NCT01048905

Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension

Phase 2 Trial for Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: UCSF Benioff Children's Hospital Oakland · Academic / Other
• Sex: All
• Age: 4 Years
• Healthy volunteers: Accepted

Summary

The primary hypothesis of this study is that glutamine supplementation will improve the erythrocyte glutamine/glutamate ratio, a biomarker of oxidative stress, hemolysis and pulmonary hypertension (PH) in sickle cell disease (SCD) and thalassemia (Thal) patients with PH. PH is defined as a tricuspid regurgitant jet velocity (TRV) on Doppler echocardiography \> 2.5 m/s. We also predict that glutamine therapy will increase arginine bioavailability and subsequently alter sickle red cell endothelial interaction that can be identified using endo-PAT technology through nitric oxide (NO) generation, leading to changes in biological markers, and clinical outcome. Specifically our second hypothesis is that oral glutamine will decrease biomarkers of hemolysis and adhesion molecules, and improve the imbalanced arginine-to-ornithine ratio that occurs in hemolytic anemias, leading to improved arginine bioavailability and clinical endpoints of endothelial dysfunction and PH in patients with SCD and Thal.

Conditions

• Pulmonary Hypertension
• Sickle Cell Disease
• Thalassemia

Interventions

Type	Name	Description
DRUG	L-Glutamine	Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children \< 15 years of age.

Timeline

• Start date: 2009-03-01
• Primary completion: 2014-03-01
• Completion: 2014-03-01
• First posted: 2010-01-14
• Last updated: 2021-06-10
• Results posted: 2021-06-10

Locations

1 site across 1 country: United States